DARMSTADT, Germany--(BUSINESS WIRE)-- Merck KGaA, Darmstadt, Germany (DAX: MRK), a leading science and technology company, and SpringWorks Therapeutics, Inc., a Stamford, Connecticut-based ...
(Reuters) - Germany's Merck KGaA said on Thursday it is in late-stage talks to acquire U.S.-based SpringWorks Therapeutics for about $3.5 billion, a deal that could give it access to a recently ...
Two months after confirming “advanced talks” for a potential merger, Stamford-based SpringWorks Therapeutics Inc. on Monday announced a definitive agreement to be acquired by Germany-based Merck KGaA ...
NEW YORK/FRANKFURT (Reuters) - Germany's Merck KGaA has struck a deal to buy U.S. biotech company SpringWorks Therapeutics for an equity value of $3.9 billion to add rare cancer therapies ahead of ...
Germany's Merck KGaA agreed to acquire U.S. biopharmaceutical company SpringWorks Therapeutics for around $3.9 billion, in a bid to expand its oncology and rare disease business. The German ...
Add Yahoo as a preferred source to see more of our stories on Google. The logo of the Merck pharmaceutical and chemical group is on a building at its headquarters in Darmstadt. Sebastian Gollnow/dpa ...
– Purchase price of $47 per share in cash represents an equity value of approximately $3.9 billion, or an enterprise value of $3.4 billion (€3.0 billion) – – Planned acquisition will immediately add ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results